Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Treatment eligibility for dementia becomes narrower at nearly every step because pharmaceutical companies, regulatory agencies, and insurance providers each impose their own restrictions based on safety, efficacy data, and cost containment. A patient diagnosed with mild cognitive decline might discover that the very drug their neurologist recommends is only approved for people whose cognitive scores fall within a specific range—sometimes excluding the earliest stages where the patient actually is. These eligibility gates exist by design: they’re meant to protect patients from medications that haven’t been tested in their particular situation, but they also mean that many people with dementia-related symptoms never qualify for the treatments being discussed in their doctor’s office.
The restrictions aren’t arbitrary. Manufacturers conduct clinical trials on carefully selected populations—often excluding people over 85, those with multiple medical conditions, or those taking certain other medications. Insurance companies then layer their own requirements on top, sometimes requiring failed trials of cheaper alternatives first. By the time a patient navigates all these barriers, their cognitive decline may have progressed past the window where that particular drug was designed to help.
Table of Contents
- Why Do Pharmaceutical Companies Narrow Eligibility Criteria?
- Cognitive Severity Thresholds Create Hard Cutoffs
- Biomarker Testing Requirements Block Access
- Insurance Restrictions Layer Additional Barriers
- Comorbidity and Drug Interaction Restrictions
- Diagnostic Requirements Demand Specialist Confirmation
- Site-of-Care and Monitoring Restrictions
- Frequently Asked Questions
Why Do Pharmaceutical Companies Narrow Eligibility Criteria?
Clinical trials must define their participant population precisely to prove a drug works for a specific group. When a company tests a new dementia medication, they typically recruit people with mild cognitive impairment or early Alzheimer’s disease—not advanced dementia—because the drug’s target is slowing early decline. Participants with other neurological conditions like Parkinson’s disease or Lewy body dementia are often excluded because their brains respond differently to medications. Someone with both Alzheimer’s disease and Parkinson’s disease might fall into a gap where no medication has been tested.
The exclusion of older adults is particularly common. A drug studied in people aged 50–85 carries uncertainty when prescribed to someone age 90, especially if that person takes multiple medications. Pharmaceutical companies don’t want to conduct costly additional trials for every age group or comorbidity combination, so they publish their data for the population they studied and let the FDA decide whether the label should be broader. Most of the time, it stays narrow.
Cognitive Severity Thresholds Create Hard Cutoffs
Many dementia treatments are only approved for mild to moderate cognitive decline because the clinical trial enrolled people in that range. Lecanemab, a monoclonal antibody that targets amyloid plaques in the brain, is approved for mild cognitive impairment and mild dementia—not moderate or advanced. A patient with moderate dementia who hears about this drug and asks their doctor if they can try it will likely hear no, because the drug wasn’t tested in people at their stage of decline. The safety and effectiveness data simply don’t exist for them.
This creates a cruel timing problem: by the time a family gets a diagnosis, seeks specialist care, and discusses options, months or even years may have passed. The patient may have already crossed the cognitive threshold where they’re eligible. The Mini-Cog or Montreal Cognitive Assessment score becomes a gatekeeper. A score of 20 might qualify; a score of 18 might not. There’s no medical reason for the exact cutoff other than that’s what the trial participants scored, and that’s what the regulatory approval specifies.
Biomarker Testing Requirements Block Access
Newer treatments require objective evidence of disease pathology—usually a positive biomarker test—before a patient can start treatment. Lecanemab requires confirmation of amyloid pathology through PET imaging or blood biomarkers like phosphorylated tau and amyloid-beta ratios. For a patient without access to a PET scanner or a laboratory that can run these tests, the medication remains out of reach even if they qualify cognitively.
Rural areas and safety-net hospitals often lack these resources. Insurance companies frequently deny coverage for biomarker testing if the patient hasn’t already met other criteria, creating a catch-22: the patient can’t afford the $3,000–$5,000 amyloid PET scan without insurance approval, but insurance won’t approve testing without evidence of cognitive impairment. Some people end up paying out of pocket or never get tested at all. Even worse, blood-based biomarkers are newer and not all insurance plans cover them yet, so a patient may be directed to an expensive imaging study instead of a simple blood draw.
Insurance Restrictions Layer Additional Barriers
Medicare and private insurers add their own eligibility requirements on top of FDA approval. Medicare may require a patient to fail or show intolerance to a less expensive medication first—a step-therapy requirement—before covering an expensive monoclonal antibody. A patient on donepezil might be told they must continue for several more months to “prove” it’s not working before insurance will consider lecanemab, even though their neurologist believes the newer drug would be more effective now. Prior authorization processes can delay treatment by weeks or months.
A neurologist submits paperwork requesting approval, and an insurance reviewer—often not a neurologist—makes the decision based on clinical criteria that may not match the patient’s specific situation. Some patients never return to follow up once they encounter this delay; others improve or decline past the eligibility window while waiting for authorization. The cost difference between drugs matters too: donepezil costs pennies per dose; lecanemab costs $26,500 per year. Insurers have strong financial incentives to keep patients on cheaper treatments, regardless of whether those treatments are optimal for that individual.
Comorbidity and Drug Interaction Restrictions
A patient with dementia who also has heart failure, kidney disease, or diabetes may find themselves ineligible for certain treatments because those conditions were excluded from the clinical trials. A common scenario: someone with both Alzheimer’s disease and atrial fibrillation takes warfarin to prevent stroke. Medications that increase bleeding risk become contraindicated, narrowing the treatment options even further. A person with mild cognitive impairment and uncontrolled hypertension might be told to optimize their blood pressure first, delaying dementia-specific treatment indefinitely.
Some eligibility restrictions exist for legitimate safety reasons. Amyloid-related imaging abnormalities (ARIA) occur in some people taking anti-amyloid monoclonal antibodies—brain microhemorrhages or microinfarcts visible only on MRI. Patients with existing brain disease, previous strokes, or certain genetic markers like APOE4 homozygosity face higher ARIA risk, so some clinicians restrict these drugs to lower-risk patients. A person who could theoretically benefit from the medication must forego it because their neuroimaging or genetics put them in a higher-risk category than the clinical trials evaluated.
Diagnostic Requirements Demand Specialist Confirmation
Many treatments require a diagnosis made or confirmed by a neurologist or dementia specialist, not a primary care physician. A person diagnosed with mild cognitive decline by their family doctor may not qualify for treatment trials until a neurologist or neuropsychologist confirms the diagnosis independently. Accessing a neurologist requires a referral, an appointment slot (which may be weeks away), and often another evaluation. Rural patients, people without transportation, and those in underserved healthcare systems face months of delay.
Neuropsychological testing—formal cognitive assessment by a psychologist—is sometimes required before treatment eligibility is confirmed. These tests take hours, cost hundreds of dollars, and may not be covered by insurance. A 78-year-old with early memory loss who wants to explore treatment options might need to invest time and money in testing before even knowing if they’re a candidate. By the time the results come back, their cognitive status may have changed.
Site-of-Care and Monitoring Restrictions
Some treatments require infusion at a specialty center or close monitoring by a neurologist—infrastructure not available everywhere. A patient in a small town may be eligible for a monoclonal antibody infusion therapy but cannot receive it because the nearest infusion center is 100 miles away. Whether they can access this care depends entirely on where they live, their transportation resources, and their ability to take time off work for regular appointments.
Monitoring also matters. Lecanemab requires baseline MRI and follow-up MRIs to screen for ARIA. A patient without access to MRI imaging at a local hospital, or whose insurance won’t cover repeat imaging, effectively cannot safely start the drug even if they meet all other criteria. The infrastructure to deliver treatment—not just the patient’s medical eligibility—becomes the limiting factor.
- —
Frequently Asked Questions
If my doctor recommends a treatment but I’m told I don’t qualify, is there anything I can do?
Ask your doctor specifically which criteria you don’t meet and whether any of them might change with time or further testing. Some insurance denials can be appealed with additional documentation. Clinical trial enrollment is another option if you’re interested in experimental treatments and meet their criteria—trials often provide free testing and medication.
Why are treatments only approved for mild or early-stage dementia?
Pharmaceutical companies conduct trials in specific populations to clearly demonstrate safety and efficacy. Testing in advanced dementia introduces variables that make it harder to prove a drug works, so manufacturers don’t pursue those approvals. The FDA approves drugs based on the evidence submitted, which means approval labels stay narrow.
Does mild cognitive impairment always mean I’ll develop Alzheimer’s disease?
No. Some people with MCI remain stable for years or never progress to dementia. Others progress more rapidly. This unpredictability is one reason treatments for MCI remain limited—it’s unclear which patients will benefit most.
Can I get a biomarker test without a referral?
Some blood-based biomarker tests can be ordered through direct-to-consumer labs, but insurance may not cover them. PET imaging almost always requires a doctor’s referral and insurance approval. Discuss with your primary care physician or neurologist whether testing makes sense for your situation.
Will more treatments become available for advanced dementia?
Possibly, but it requires companies to conduct trials specifically in that population. The cost and regulatory complexity mean this happens slowly. For now, most disease-modifying treatments target early stages.
What if I don’t have a neurologist nearby?
Telemedicine appointments with neurologists are increasingly available and may satisfy diagnostic requirements, but they don’t solve the problem of accessing infusions or imaging at a specialty center. Ask your primary care doctor whether they can coordinate care with a remote specialist. —
